Avidity Biosciences (NASDAQ:RNA) is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of therapeutics known as antibody-oligonucleotide conjugates (AOCs). These conjugates harness the specificity of antibodies to deliver oligonucleotide payloads directly to target cells, with an initial emphasis on addressing rare and serious muscle-targeted diseases. The company’s approach seeks to overcome delivery challenges historically associated with oligonucleotide therapies by combining established antibody targeting technologies with precision genetic modulation.
The company’s pipeline includes multiple preclinical and clinical programs aimed at treating neuromuscular disorders, with lead candidates advancing in conditions such as Duchenne muscular dystrophy and other rare muscle diseases. Avidity’s AOC platform is designed to improve cellular uptake, biodistribution and durability of oligonucleotides, potentially enabling lower dosing and enhanced therapeutic profiles. Beyond its lead indications, the platform has broad applicability across a range of genetic and neuromuscular disorders, positioning the organization for future expansion into additional therapeutic areas.
Founded in 2017 and headquartered in San Diego, California, Avidity Biosciences operates research and development sites in both the United States and Europe. The company was built on foundational research in oligonucleotide and antibody engineering, drawing talent from leading academic institutions and the biotech industry. Avidity maintains collaborations with academic laboratories and biotechnology partners to accelerate discovery efforts and validate new applications of its AOC technology across different disease targets.
Led by Chief Executive Officer Karim Galil, Avidity’s leadership team brings deep expertise in biotechnology, drug development and cell-targeting platforms. The company’s management includes seasoned professionals in medicinal chemistry, clinical sciences and regulatory affairs, all working to advance the AOC portfolio through clinical milestones. With a commitment to transforming treatment paradigms for patients with unmet medical needs, Avidity Biosciences continues to build a robust pipeline and strengthen its scientific and operational capabilities.
